Breaking · World's first CAR-T for gastric/GEJ cancer approved in China.Check if you qualify — free

Back to Resources
Cancer Care

Treatment Explained

Understand Your Options Before You Decide.

Clear, balanced explanations of cancer treatment approaches available in China — from conventional surgery and chemotherapy to immunotherapy, targeted therapy, and cell therapy.

Articles & Guides

August 14, 2026
Leukemia Guide

Acute Lymphoblastic Leukemia (ALL) Treatment Options for Adults and Children

A structured guide for international patients, caregivers, and physicians on how ALL is treated in children versus adults — covering B-ALL vs T-ALL, Ph-positive ALL and TKIs, multi-phase chemotherapy, MRD-based risk, when transplant is discussed, relapsed B-ALL options (blinatumomab, inotuzumab, CD19 CAR-T), haploidentical family donors, and remote MDT review in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • B-ALL vs T-ALL, and why genetics including BCR-ABL1 (Ph-positive ALL) change the drug list
  • Paediatric multi-phase chemotherapy versus adult pathways and paediatric-inspired AYA regimens
  • MRD as a decision tool for intensification, immunotherapy, or transplant evaluation
  • Relapsed B-ALL: blinatumomab, inotuzumab ozogamicin, and CD19 CAR-T — including China adult product Yuanruida
  • When haploidentical transplant is relevant if no matched unrelated donor is found (CCBMTR paediatric context)

Important Facts

  • Most children with standard-risk ALL are treated with chemotherapy first; transplant is not automatic
  • Adult ALL more often involves TKI (if Ph-positive), earlier transplant discussion, and CAR-T at relapse
  • Paediatric CAR-T access in China should not be assumed from the adult B-ALL commercial label
  • Remote MDT review can clarify sequencing before any travel, leukapheresis, or donor work-up
June 23, 2026
ADC / Targeted Therapy

What Is Iza-Bren (BL-B01D1)? The First EGFR×HER3 Bispecific ADC Approved for Nasopharyngeal Carcinoma in China

On 23 June 2026, China's NMPA approved iza-bren (伦康依隆妥单抗, BL-B01D1) — the first globally approved EGFR×HER3 bispecific antibody-drug conjugate — for adults with recurrent or metastatic nasopharyngeal carcinoma after failure of at least second-line systemic therapy including platinum chemotherapy and PD-1/PD-L1 inhibitors. Covers dual EGFR/HER3 targeting mechanism, Ed-04 topoisomerase I payload (DAR 8), Phase III BL-B01D1-303 trial results published in The Lancet (cORR 54.6% vs 27.0%, mPFS 8.38 vs 4.34 months), safety profile, BMS global licensing deal, pipeline indications (ESCC, TNBC), physician-led treatment decision framework, and what international NPC patients should ask their doctor before any later-line planning.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • First-in-class EGFR×HER3 bispecific ADC — globally first approved drug of this class (China NMPA, June 2026)
  • Approved indication: R/M NPC after ≥2L systemic therapy including platinum + PD-1/PD-L1 inhibitor failure
  • Mechanism: dual EGFR/HER3 blockade + topoisomerase I inhibitor payload; bispecific design may address antigen heterogeneity and reduce skin toxicity vs single-target EGFR agents
  • Phase III BL-B01D1-303 (55 Chinese centres, 386 patients): cORR 54.6% vs 27.0%, mDoR 8.5 vs 4.8 months, mPFS 8.38 vs 4.34 months (HR 0.44) vs physician's-choice chemotherapy
  • Pipeline: ESCC and TNBC marketing applications accepted; 14 Phase III trials across multiple solid tumours; BMS co-development deal (USD 8.4B)

Important Facts

  • Iza-bren is approved for a specific heavily pre-treated R/M NPC population — not first-line or all NPC patients
  • Trial results apply to the studied population; individual response and survival cannot be predicted from group data
  • China's southern oncology centres manage among the world's largest NPC caseloads — relevant for international patients from endemic regions considering later-line review
  • Structured MDT review based on full treatment history is the appropriate first step before assuming iza-bren eligibility or planning travel
  • A drug approval creates a medical option for physicians — patients should not self-select iza-bren; all treatment decisions must follow the treating oncologist's advice
June 15, 2026
Treatment Guide

How Does Lorlatinib Work for Advanced ALK-Positive Non-Small Cell Lung Cancer?

A structured guide for international patients, caregivers, and physicians on lorlatinib — a third-generation ALK inhibitor for advanced ALK-positive NSCLC. Covers how lorlatinib overcomes ALK resistance mutations (G1202R, compound mutations), its macrocyclic mechanism of action, CROWN trial progression-free survival and intracranial outcomes, exceptional blood-brain barrier penetration and brain metastases management, distinct side effects (hyperlipidaemia, CNS cognitive and mood effects, oedema), first-line vs post-resistance use sequencing, what happens after lorlatinib failure, and what this means for international patients considering evaluation or treatment in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • What ALK-positive NSCLC is — ALK rearrangement biology, who is more likely to be affected, and why comprehensive molecular testing is essential before any targeted therapy decision
  • Three generations of ALK inhibitors — crizotinib (1st gen), alectinib/brigatinib/ceritinib (2nd gen), lorlatinib (3rd gen) — and where lorlatinib fits in the treatment sequence
  • Lorlatinib mechanism — macrocyclic structure, G1202R and other resistance mutation coverage, ROS1 inhibition, and why lorlatinib overcomes what second-generation drugs cannot
  • CROWN trial key findings — median PFS not yet reached at 5 years with lorlatinib vs crizotinib; ~64% of patients progression-free at 3 years; 12-month intracranial progression rate ~3% vs ~33% with crizotinib
  • CNS penetration and brain metastases — how lorlatinib crosses the blood-brain barrier, intracranial response data, and implications for patients with existing or high-risk brain metastases
  • Side effect profile — hyperlipidaemia (majority of patients, requires statin management), CNS effects (cognitive changes, mood alterations, speech effects unique to lorlatinib), oedema, weight gain, peripheral neuropathy

Important Facts

  • Lorlatinib is now a first-line recommendation for advanced ALK-positive NSCLC based on CROWN trial data — but the choice between lorlatinib and alectinib first-line requires specialist discussion as no direct head-to-head trial exists
  • CNS effects (cognitive, mood, speech) are unique to lorlatinib and related to its strong blood-brain barrier penetration — caregivers should be aware and proactive in reporting changes to the oncology team
  • Post-lorlatinib resistance (compound ALK mutations) is difficult to address with currently available drugs — treatment sequencing strategy should be discussed with a specialist before starting lorlatinib
  • Lorlatinib (洛拉替尼) is NMPA-approved and available in China; international patients can access evaluation at major Chinese oncology centres via remote MDT consultation before any travel decision
June 15, 2026
Treatment Guide

What Are the Most Promising New Treatments for Multiple Myeloma — and Could They Lead to a Cure?

A structured guide for international patients, caregivers, and physicians on the newest treatment innovations for multiple myeloma — covering bispecific T-cell engaging antibodies (teclistamab, elranatamab, talquetamab), next-generation BCMA-targeted CAR-T therapy (cilta-cel, ide-cel), CELMoDs (mezigdomide, iberdomide), antibody-drug conjugates (belantamab mafodotin), quadruplet induction therapy, MRD-guided treatment decisions, the concept of a functional cure, and what these advances mean for international patients considering evaluation or treatment in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Bispecific antibodies explained — teclistamab (BCMA×CD3), elranatamab (BCMA×CD3), and talquetamab (GPRC5D×CD3) — a new off-the-shelf immunotherapy class with meaningful response rates in heavily pre-treated myeloma
  • Next-generation CAR-T for myeloma — cilta-cel and ide-cel extended follow-up data, early-line use in CARTITUDE-4, and the significance of durable MRD-negative responses
  • CELMoDs (mezigdomide, iberdomide) — how these next-generation immunomodulatory compounds work after lenalidomide and pomalidomide resistance
  • Antibody-drug conjugates — belantamab mafodotin mechanism, response data, and combination trials; BCMA and GPRC5D ADCs in development
  • Quadruplet therapy and MRD negativity — what 60%+ MRD-negative response rates in Dara-VRd mean for treatment goals and long-term disease control
  • Is a cure possible? The "operational cure" concept, MRD-guided treatment discontinuation trials, and why individual prognosis cannot be predicted from population data

Important Facts

  • Multiple myeloma is not currently curable for most patients, but a growing number achieve deep and sustained MRD-negative remissions — prompting careful discussion about long-term disease control for certain individuals
  • Bispecific antibodies offer a new pathway for patients who have relapsed after standard agents and BCMA-targeted therapy — talquetamab (GPRC5D target) may be active even after prior BCMA exposure
  • For international patients, a remote MDT consultation is the appropriate starting point — to evaluate diagnosis, prior treatment history, and eligibility before any travel or treatment decisions are made
  • China has active BCMA-targeted CAR-T programs and participates in investigational novel agent trials — structured evaluation can clarify what may be accessible for a specific patient profile
June 6, 2026
Leukemia Guide

What Are Some Successful Leukemia Treatments Other Than a Bone Marrow Transplant?

A structured guide for international patients, caregivers, and physicians on the full range of leukemia treatments that do not require bone marrow transplantation — covering chemotherapy, targeted therapy (TKIs, FLT3 inhibitors, IDH inhibitors, venetoclax, BTK inhibitors), immunotherapy (blinatumomab, inotuzumab ozogamicin), CAR-T cell therapy, maintenance strategies, MRD monitoring, and how treatment approach differs across AML, ALL, CML, and CLL.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Why bone marrow transplant is not the default — when it is and is not indicated across leukemia subtypes
  • Chemotherapy in leukemia: induction, consolidation, maintenance, and CNS prophylaxis — when chemo alone may be sufficient
  • Targeted therapy options by mutation: TKIs for CML/Ph+ ALL, FLT3 inhibitors, IDH inhibitors, venetoclax, BTK inhibitors — and why molecular testing is essential
  • Immunotherapy approaches: blinatumomab (bispecific antibody), inotuzumab ozogamicin, gemtuzumab ozogamicin, anti-CD20 therapy
  • CAR-T therapy for relapsed/refractory leukemia — eligibility considerations and China's experience in hematologic malignancies
  • Maintenance therapy and MRD monitoring: how measurable residual disease results guide treatment escalation or deferral of transplant

Important Facts

  • Many leukemia patients are successfully treated without transplant — the need for transplant depends on disease subtype, genetic risk, and treatment response
  • Targeted therapy has transformed outcomes in CML (oral TKIs), Ph+ ALL, FLT3-mutated AML, and CLL (BTK inhibitors, venetoclax) — often replacing the need for transplant entirely
  • For international patients, a remote MDT second opinion can clarify whether transplant is truly needed and whether targeted or cellular therapy alternatives are appropriate
  • CAR-T evaluation and haploidentical transplant access in China are relevant for patients facing relapse or donor shortage when local options are limited
June 2, 2026
Treatment Guide

Prostate Cancer: Surgery or SBRT — Which Is the Better Treatment?

A clear evidence-based comparison of radical prostatectomy (surgery) and SBRT / SABR (stereotactic body radiation therapy) for localised prostate cancer — cancer control rates, side effect profiles (urinary incontinence, erectile dysfunction, bowel toxicity), patient selection factors, and when a second opinion from a urological and radiation oncology MDT is advisable.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Both surgery and SBRT achieve similar long-term cancer control for localised low-to-intermediate risk prostate cancer
  • Side effect profiles differ significantly: urinary incontinence is more common early after surgery; bowel toxicity is specific to radiation
  • Erectile dysfunction timing differs: immediate after surgery, gradual (12–18 months) after SBRT
  • Seven patient-specific factors that guide the choice — risk group, age, anatomy, baseline symptoms, lifestyle priorities
  • When prostate cancer requires more than surgery or SBRT alone: high-risk disease, node involvement, oligometastatic disease

Important Facts

  • Neither surgery nor SBRT is universally better — the right choice depends on individual risk group, anatomy, symptoms, and quality-of-life priorities
  • An MDT review with both a urological surgeon and a radiation oncologist is strongly advisable before committing to a single modality
  • SBRT (5 sessions) is logistically better suited to patients who travel for treatment; surgery requires a longer local recovery period
  • International patients can access a remote MDT consultation before deciding whether to proceed with treatment in China or at home
May 26, 2026
Treatment Guide

What to Expect When Chemotherapy Continues After Cancer Seems Gone

A clear guide for international patients and caregivers on why chemotherapy may continue after scans show no visible cancer — covering NED (no evidence of disease), adjuvant therapy, consolidation chemotherapy, microscopic residual disease, recurrence risk, emotional confusion after remission, supportive care in China, and when an MDT second opinion may help clarify decisions.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Four common patient reactions addressed directly: why continue if cancer is gone, am I being overtreated, does this mean cancer is still there, and why continue if I feel weak
  • What NED (no evidence of disease) actually means — and what it does not guarantee about microscopic residual disease
  • Why cancer treatment often happens in phases: induction, surgery, adjuvant, consolidation, maintenance, and immunotherapy each serve different biological purposes
  • What continued chemotherapy means in solid tumours, blood cancers, and paediatric cancers — each cancer type explained separately
  • Why emotional distress can increase after cancer appears gone — and how caregivers can support without adding pressure
  • Supportive Care in China: TCM and integrative approaches alongside chemotherapy — not as replacements — for fatigue, sleep, appetite, and emotional stress

Important Facts

  • NED means cancer is not currently detectable — not that it is certainly gone; microscopic residual disease may remain even after clear scans
  • Post-remission chemotherapy is often a planned phase of care designed from the start, not a response to treatment failure
  • For international patients, a remote MDT review can clarify why continued chemotherapy is recommended and how treatment sequencing works across healthcare systems
  • Supportive care in China — including TCM-based approaches — may improve quality of life during prolonged chemotherapy without replacing standard oncology treatment
May 24, 2026
Blood Cancer & Transplant Guide

What to Expect When Considering Haploidentical Transplantation in China

A structured guide for international patients and caregivers on haploidentical stem cell transplantation (haplo-HSCT) in China — covering how the procedure works, why China has extensive experience in alternative donor transplantation, how to evaluate donor options, what the transplant process involves, emotional challenges for families, a five-step practical framework, supportive care during recovery, caregiver roles, and what to consider before making travel decisions.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Four direct answers: what haploidentical transplantation is, why China is experienced in haplo-HSCT, whether outcomes are worse than matched donor transplant, and when a second opinion helps
  • Why donor availability is no longer the only question — disease status, MRD, organ function, urgency, and alternative therapy considerations all matter
  • What international patients should understand: pre-transplant evaluation, prolonged local stay, caregiver preparation, and post-transplant follow-up across healthcare systems
  • Emotional challenges for families: uncertainty, parental donor pressure, and realistic recovery timelines
  • Five-step framework: diagnosis clarity, donor review, protocol understanding, caregiver preparation, post-transplant planning
  • Supportive Care in China: TCM and integrative approaches alongside transplant medicine — used as complementary, not replacement, care

Important Facts

  • China has large clinical experience in haploidentical transplantation, particularly for blood cancers without a matched sibling donor
  • Modern haploidentical transplant outcomes have improved significantly compared with older protocols — results depend heavily on disease type, patient age, and transplant centre experience
  • For international patients, a remote MDT review before travel can clarify transplant eligibility, donor feasibility, expected timelines, and what preparation is required
  • Transplantation is a long treatment journey — preparation for post-transplant recovery, caregiver roles, and cross-border follow-up matters as much as the transplant itself
May 22, 2026
Advanced Cancer Guide

When Should Terminal Cancer Patients Reconsider Chemotherapy Side Effects?

A calm, structured guide for international cancer patients and caregivers on when chemotherapy side effects may outweigh the benefits in terminal cancer — covering how to evaluate treatment burden versus benefit, a five-step decision framework, when MDT review or a second opinion in China may help clarify goals, supportive care including TCM alongside or instead of chemotherapy, and caregiver guidance.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Four direct answers: when side effects outweigh benefits in terminal cancer, how to decide on another cycle, whether stopping means stopping all care, and when to seek a second opinion
  • Five-step framework: clarify the chemotherapy goal, measure actual treatment burden, ask what happens without it, include the patient's values, and reassess after every cycle
  • What MDT evaluation in China may include: staging reassessment, prior treatment review, molecular testing, palliative planning, and travel feasibility
  • Supportive care in China: TCM, acupuncture, pain control, appetite and fatigue support — alongside, not instead of, chemotherapy or palliative care
  • Caregiver guidance: questions that help patients express values, practical support roles, and why caregivers need their own support

Important Facts

  • Stopping chemotherapy is not giving up — it can be a medically appropriate and compassionate decision when treatment no longer serves the patient's goals
  • Palliative care can run alongside active cancer treatment at any stage, not only near the end of life — ASCO guidelines support early integration
  • For international patients, an online MDT consultation can clarify whether further chemotherapy is medically reasonable before any travel decision is made
  • Supportive care in China — including TCM-based approaches — may improve comfort and quality of life regardless of whether chemotherapy continues
May 20, 2026
Treatment Decision Guide

What to Expect When Considering CAR-T Therapy and Modern Cancer Treatment Options

A realistic guide for international cancer patients and caregivers on common CAR-T therapy misconceptions — covering why advanced treatment is not automatically easier, what CAR-T actually involves as a multi-stage process, why recovery remains challenging after intensive therapies, a five-step decision framework before pursuing CAR-T, how supportive care in China fits into advanced therapy recovery, and caregiver preparation guidance.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Three major CAR-T misconceptions: universal cure, immediate permanent effect after infusion, and complete replacement of all other treatments — each addressed with clinical reality
  • Why advanced therapy does not mean easier therapy: comparison of common patient assumptions versus what CAR-T may actually involve including CRS, neurological side effects, prolonged monitoring, and infection risk
  • Five-step decision framework before pursuing CAR-T: clarify exact diagnosis, identify treatment goal, evaluate logistical realities, understand the supportive care plan, and prepare emotionally for uncertainty
  • What patients underestimate about CAR-T logistics: multi-stage process (evaluation → leukapheresis → manufacturing → conditioning → infusion → monitoring), variable recovery timelines, and broader pathway integration
  • Supportive Care in China: TCM and integrative approaches used alongside CAR-T and standard oncology — not as replacements — for fatigue, nutrition, sleep, and recovery support
  • Caregiver preparation: why families cope better with honest expectation-setting, early logistics clarity, and normalized emotional support access

Important Facts

  • CAR-T is a multi-stage process spanning weeks to months — not a single infusion event followed by immediate recovery
  • Advanced cancer therapy does not eliminate recovery challenges: fatigue, immune suppression, emotional exhaustion, and uncertainty about remission duration are common and real
  • For international patients, online MDT consultation before travel helps clarify CAR-T eligibility, realistic timelines, and logistical requirements specific to the individual patient profile
  • Supportive care is not secondary to CAR-T — it is essential for helping patients tolerate and recover from intensive advanced therapies
May 20, 2026
Patient & Caregiver Guide

What to Expect When Frequent Travel Becomes Part of Cancer Treatment

A practical guide for international cancer patients and caregivers on the real-world impact of repeated travel for cancer treatment — covering physical and emotional exhaustion, family burden, coordination complexity, when to seek a second opinion before traveling, and how supportive care in China may help reduce the travel burden.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Four categories of treatment travel impact: physical, emotional, financial, and practical coordination
  • Why travel gets harder as cancer treatment continues — cumulative fatigue, scheduling demands, and changing mobility
  • When to reassess travel sustainability: six clinical and quality-of-life signals to discuss with doctors
  • Why coordination matters as much as treatment itself for international patients in China
  • Supportive care in China alongside treatment: TCM, acupuncture, nutrition, rehabilitation as complementary approaches
  • Five-step practical framework: timeline clarification, records preparation, travel tolerance discussion, caregiver planning, and recovery scheduling

Important Facts

  • Frequent treatment travel creates cumulative physical, emotional, financial, and logistical burden — not just a scheduling challenge
  • Online MDT consultation before international travel helps clarify whether travel is medically warranted and what coordination is realistically required
  • Caregiver exhaustion during repeated treatment travel is common and deserves structured support, not just patient-centred planning
  • Supportive care in China — including TCM-based approaches — can help patients tolerate treatment more safely during extended travel journeys
May 19, 2026
Supportive Care Guide

What to Expect When Supportive Care Becomes Part of Cancer Treatment

A practical guide for international cancer patients and caregivers on integrating supportive care into cancer treatment — covering symptom management, TCM alongside chemotherapy and immunotherapy in China, a five-step practical framework, caregiver support, and when to seek a second opinion during active treatment.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • What supportive care actually includes during active cancer treatment: symptom control, nutrition, rehabilitation, psychological support, and integrative approaches
  • How supportive care helps patients continue chemotherapy, radiation, immunotherapy, and targeted therapy with fewer treatment interruptions
  • How TCM-based supportive care in China fits alongside standard oncology treatment — not instead of it
  • Five-step practical framework: monitor early, clarify goals, include caregivers, address emotional health, and plan recovery from the start
  • For international patients: pre-travel coordination, MDT review for uncertainty, and TCM-based supportive care options available at Chinese oncology hospitals

Important Facts

  • Supportive care is part of cancer treatment, not separate from it — and it can start at diagnosis
  • TCM-based approaches used in China for supportive care include acupuncture, herbal medicine, and therapeutic nutrition — all alongside, not replacing, systemic treatment
  • Early supportive care prevents treatment interruptions and helps patients sustain longer treatment journeys more safely
  • For international families, coordinated care planning reduces logistical and emotional pressure during complex cross-border treatment processes
May 18, 2026
Emerging Therapy

Is Ivonescimab the Next Big Breakthrough in Oncology?

A calm, structured guide for international cancer patients and caregivers on what Ivonescimab actually is — covering the PD-1 and VEGF dual-targeting mechanism, why lung cancer became the major clinical focus, how to avoid oversimplified breakthrough thinking, why modern oncology is becoming more biologically individualized, why international patients are watching China's oncology innovation more closely, what to ask before pursuing emerging immunotherapy, why second opinions matter more with experimental therapies, supportive care during advanced immunotherapy, and the emotional reality behind "next big breakthrough" headlines.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Why Ivonescimab matters scientifically: PD-1 blockade + VEGF inhibition in a single bispecific antibody — addressing both immune activation and tumour microenvironment suppression simultaneously
  • Why lung cancer (especially EGFR-mutated NSCLC) became the major clinical focus, and what the early data does and does not show
  • Eight structured questions patients should ask about any new therapy — separating realistic medical discussion from headline-driven optimism
  • Why international patients are watching China's oncology innovation more closely: immunotherapy, bispecific antibodies, ADCs, CAR-T, ASCO/ESMO data presentation
  • Ten specific questions to ask before pursuing newer immunotherapy — covering biomarkers, approval status, survival vs. response data, and eligibility
  • Supportive Care in China: TCM and acupuncture alongside immunotherapy — preserving patient strength during complex treatment planning

Important Facts

  • Ivonescimab represents a "dual-target" bispecific antibody approach — a broader trend in oncology moving beyond single-pathway checkpoint blockade alone
  • Early enthusiasm about oncology drugs needs to be evaluated against mature survival data, patient population specifics, and real-world outcomes — not early results alone
  • China is becoming an active source of oncology innovation — not just a treatment destination — with increasing visibility at global oncology conferences
  • For international patients, structured MDT review can assess whether newer therapies are biologically and clinically relevant to a specific patient before any travel decision is made
May 17, 2026
Treatment Decision Guide

What Should Cancer Patients Do When Traditional Treatments Fail?

A calm, structured guide for international cancer patients and caregivers when chemotherapy, immunotherapy, targeted therapy, radiation, or surgery stops working — covering why "treatment failed" needs careful interpretation, four critical questions to ask first, six treatment categories that may still exist (targeted therapy, immunotherapy combinations, ADCs, cellular therapy, local treatment, palliative care), a five-step decision framework, what China-based evaluation involves, supportive care during difficult decisions, and caregiver guidance.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Why "treatment failed" means different things medically — and why the right question is "what exactly happened, and what does that tell us about next steps?"
  • Four critical questions before choosing another treatment: Is this true progression? Should pathology be reviewed? Should molecular testing be repeated? What is the treatment goal now?
  • Six treatment option categories explained: targeted therapy, immunotherapy combinations, antibody-drug conjugates, cellular therapy, local treatment for symptoms, palliative and supportive care
  • Five-step decision framework: reconstruct the timeline, identify missing information, clarify whether active treatment still makes sense, ask about clinical trials early, consider MDT review
  • What China-based evaluation after treatment failure may include: pathology review, imaging reassessment, expanded molecular testing, CAR-T assessment, clinical trial feasibility, supportive care coordination
  • Supportive Care in China: TCM and acupuncture alongside — not instead of — standard oncology treatment, helping patients maintain strength during difficult decision periods

Important Facts

  • "Standard treatment has failed" does not always mean "no meaningful options remain" — it means the case needs structured reassessment
  • Repeat biomarker testing after progression may reveal new targets or trial eligibility not present at initial diagnosis, as cancer biology evolves under treatment pressure
  • Clinical trial eligibility inquiry should happen early — waiting too long may close eligibility windows as performance status or organ function changes
  • For international patients, remote MDT review in China can evaluate options before any travel decision is made
May 16, 2026
Immunotherapy Guide

What Happens If Immunotherapy and Third-Line Chemotherapy Fail? Can Another Immunotherapy Still Help?

A calm, structured guide for international cancer patients and caregivers when immunotherapy and third-line chemotherapy have not worked — covering why cancers become resistant to immunotherapy, five specific resistance mechanisms, newer immune therapies being explored (ADCs, bispecific antibodies, CAR-T, TIL therapy, combination checkpoint blockade), why clinical trials become more important at this stage, what patients should ask their oncologist, China context for MDT review and trial access, supportive care during late-line decisions, the emotional reality of advanced treatment failure, and caregiver guidance.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Why "immunotherapy failed" means different things depending on cancer type, prior drug, and resistance mechanism — and why generalizations can mislead
  • Five immunotherapy resistance mechanisms: antigen presentation loss, immunosuppressive microenvironment, T-cell exhaustion, new mutations, alternative resistance pathways
  • Six newer immune approaches being explored: ADCs, bispecific antibodies, CAR-T, TIL therapy, combination checkpoint blockade, cancer vaccines and CAR-NK
  • Ten specific questions to ask after third-line failure — covering molecular retesting, trial eligibility, treatment goals, realistic benefit, and MDT review
  • Why some international patients explore options in China: MDT infrastructure, clinical trial access, cellular therapy programs, precision oncology review
  • Supportive Care in China: TCM and acupuncture alongside — not instead of — later-line oncology treatment, with important safety note for immunotherapy interactions

Important Facts

  • Progression after one immunotherapy drug does not automatically mean all immune-based treatments will be ineffective — resistance is biologically specific
  • Updated molecular testing after treatment failure may be more informative than tests done at initial diagnosis, as tumor biology can evolve during treatment
  • Clinical trials at the later-line stage are not last-resort experiments — they can provide access to newer agents genuinely ahead of standard practice
  • For international patients, remote MDT review in China can assess options before any travel commitment is made
May 11, 2026
Cell Therapy Guide

What Should Patients Know About CAR-T Therapy for Solid Tumors?

A calm, structured guide for international patients and caregivers on CAR-T therapy for solid tumors — covering why solid tumors are so much harder than blood cancers, what the CT041 Claudin18.2 breakthrough means, other approaches under study (pancreatic, liver, glioblastoma), what patients must understand before considering CAR-T, international patient context for cell therapy development in China, supportive care in China, and a five-question FAQ.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Why solid tumors have been so much harder than blood cancers for CAR-T: tumor microenvironment suppression, physical barriers to infiltration, genetic heterogeneity, and toxicity challenges
  • Why the CT041 (satri-cel) development matters: first solid-tumor CAR-T to file for regulatory approval globally, Lancet / ASCO 2025 data for Claudin18.2-positive gastric cancer
  • Other solid-tumor CAR-T approaches under study: mesothelin for pancreatic cancer, GPC3 for liver cancer, EGFR, CAR-NK, TIL therapy, armored CAR-T, regional infusion, immunotherapy combinations
  • Four key things patients must understand before considering CAR-T: experimental status, highly specific eligibility, complex treatment process, and central role of clinical trials
  • International patient context: what treatment discussions in China may involve — trial eligibility, pathology, biomarker testing, MDT assessment, logistics coordination
  • Supportive Care in China: TCM and integrative approaches alongside — not instead of — advanced oncology treatment, with important safety note for CRS and immune-related effects

Important Facts

  • CAR-T for solid tumors has moved from largely theoretical to early clinical reality — but remains highly specific, experimental, and not broadly available outside trials
  • The CT041 Claudin18.2 breakthrough is a meaningful milestone for advanced gastric cancer — not a universal solution for all solid tumors
  • Eligibility requires specific molecular testing, prior treatment history review, and MDT evaluation — not general interest in cell therapy
  • For international patients, a structured online MDT consultation is the appropriate first step — confirming whether any approach applies to the specific case before travel or commitment
May 10, 2026
Treatment Guide

What Happens If Cancer Stops Responding to the Same Chemotherapy?

A calm, structured guide for international patients and caregivers on chemotherapy resistance — covering why cancer can become resistant after a treatment break, four core questions answered directly, how oncologists evaluate response duration and molecular changes, what questions to ask when resistance is suspected, what international patients should understand about resistant or recurrent cancer treatment planning in China, how TCM-based supportive care is coordinated alongside standard oncology treatment, and what to do next.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Four direct answers: why cancer becomes resistant after a treatment break, whether resistance means options are over, why chemotherapy works initially but not later, and whether treatment breaks cause resistance
  • Why cancer biology changes over time — tumor evolution, resistant cell populations, altered drug metabolism, immune evasion — and what this means for reassessment
  • Four questions to ask if resistance is suspected: cause confirmation, molecular retesting, realistic treatment goals, and whether MDT review would help
  • How oncologists evaluate resistance: response duration, molecular reassessment, cumulative toxicity — and what all three mean for the next treatment decision
  • What international patients should know about resistant or recurrent cancer treatment planning in China: molecular retesting, targeted therapy, immunotherapy, CAR-T, transplant, clinical trials
  • Supportive Care in China: TCM alongside standard treatment for fatigue, appetite, sleep, and emotional stress during complex cancer care — never in place of systemic therapy

Important Facts

  • Chemotherapy resistance reflects tumor biology — not patient failure — and does not automatically mean all treatment options are exhausted
  • Repeat molecular or genomic testing may be essential after resistance develops, as tumor biology can change significantly over time
  • For international patients, a structured MDT review in China can assess pathology, molecular findings, imaging, and prior treatment history remotely before any travel decision
  • Resistance usually means the disease strategy needs re-evaluation — not that treatment possibilities have ended
May 8, 2026
Treatment Guide

Can Leukemia Be Cured? Treatment Options, Remission, and What International Patients Should Know

A calm, structured guide for international patients and caregivers on whether leukemia can be cured — covering the difference between remission and cure, why leukemia type and molecular features matter, when stem cell transplantation or CAR-T therapy may be relevant, five questions to ask after diagnosis, what international patients should understand about leukemia treatment in China, and how TCM-based supportive care is coordinated alongside standard oncology treatment.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Four direct answers: can leukemia be cured, what is the difference between remission and cure, why some patients need stem cell transplant, and how newer therapies are changing leukemia treatment
  • Why "leukemia" is not one disease — how AML, ALL, CML, CLL, and APL behave very differently and why diagnosis precision matters before any treatment decision
  • Three factors that make leukemia decisions especially difficult: rapid progression, treatment intensity, and prognosis depending on hidden molecular factors
  • Five questions to ask after a leukemia diagnosis: exact type, genetic/molecular testing needed, treatment goal, transplant role, and when to seek a second opinion or MDT review
  • What international patients should understand about leukemia treatment coordination in China: pathology review, donor coordination, CAR-T eligibility, and continuity planning
  • Supportive Care in China: TCM alongside chemotherapy, targeted therapy, or transplantation — with important immunocompromise safety note

Important Facts

  • Leukemia type, molecular mutations, and measurable residual disease (MRD) status are among the most important factors in predicting outcomes and guiding treatment
  • Remission and cure are not the same — ongoing monitoring and sometimes maintenance therapy remain important even after leukemia appears undetectable
  • For international patients, cross-border leukemia care is medically complex and requires structured record preparation, infection assessment, and donor coordination
  • MDT review in China can often be arranged remotely before any travel decision, allowing pathology and molecular findings to be evaluated by a specialist team
May 4, 2026
Treatment Guide

How to Decide Between Active Surveillance and Surgery After a Prostate Cancer Diagnosis

A calm, structured guide for international patients and caregivers on one of the most common misconceptions in prostate cancer care — that immediate surgery is always safer than active surveillance — covering risk category evaluation, quality-of-life trade-offs, a five-step decision framework, caregiver guidance, supportive care in China, and how MDT review supports informed treatment decisions.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Four direct answers to the most common patient questions: does active surveillance mean ignoring cancer, why doctors disagree, whether surgery is always safest, and why these decisions are emotionally difficult
  • What patients should evaluate before choosing — risk category, personal priorities, quality-of-life trade-offs, second pathology review, and matching treatment intensity to disease biology
  • What international patients should know about prostate cancer care in China: MRI staging, pathology review, robotic surgery, MDT consultation, and cross-border coordination
  • Supportive Care in China: TCM and integrative approaches alongside standard oncology treatment for fatigue, stress, sleep, and recovery support
  • The caregiver role: how partners shape treatment decisions, where they help, and where they may unintentionally increase pressure
  • Five-step framework for what to do next: confirm risk category, review pathology, evaluate priorities, consider second opinion, understand all pathways

Important Facts

  • Active surveillance is a structured, evidence-based strategy — not neglect — for carefully selected low-risk prostate cancer patients
  • The most useful question is not "Surgery or surveillance?" but "Which strategy fits this cancer and this patient's long-term priorities?"
  • Quality-of-life trade-offs (urinary function, sexual function, anxiety) must be part of the treatment conversation — not an afterthought
  • For international patients, structured MDT review can evaluate diagnosis, imaging, and treatment options remotely before any travel decision
April 30, 2026
Treatment Guide

Stage 4 Cancer Remission: How Often It Happens and What Makes It Possible

A calm, honest guide for international patients and caregivers on understanding stage 4 cancer remission — what complete remission, partial remission, stable disease, and long-term disease control mean, which cancer types are more likely to respond, what biological and molecular factors influence treatment response, a five-step decision framework for evaluating remission possibilities, and how MDT review in China supports realistic, case-specific treatment planning.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • What remission means in stage 4 cancer: complete remission, partial remission, stable disease, NED, and long-term disease control — and why durable remission differs from cure
  • Which stage 4 cancers are more likely to achieve meaningful remission: blood cancers, immunotherapy-responsive melanoma, lung cancer with actionable mutations, metastatic breast cancer subtypes, and oligometastatic disease
  • What makes remission more possible: targetable mutations, immunotherapy sensitivity, limited metastatic spread, patient condition — and why two patients with the same stage can have very different outcomes
  • Five-step decision framework: confirm subtype and staging details, review biomarkers, clarify treatment goal, understand available treatments, consider MDT review
  • Questions to ask your oncologist about remission possibilities — turning an emotional question into a structured medical conversation
  • Supportive Care in China: TCM and integrative approaches to support treatment tolerance and quality of life throughout stage 4 treatment

Important Facts

  • Stage 4 remission is possible but highly individualised — general statistics are less meaningful than a case-specific assessment
  • Durable remission can be a deeply meaningful goal in stage 4 cancer, even when doctors use careful language about the word "cure"
  • Biomarker and molecular testing is essential before assessing remission potential — patients should confirm which tests have been completed
  • MDT review provides a structured framework for evaluating realistic treatment goals and available options — applicable before any travel commitment
April 29, 2026
Treatment Guide

Blood Cancer Treatments Beyond Chemotherapy and CAR T

A calm, structured guide for international patients and caregivers on the full landscape of blood cancer treatment options beyond chemotherapy and CAR T — covering targeted therapies (TKIs, BTK inhibitors, BCL-2, proteasome inhibitors), immunotherapy (monoclonal antibodies, bispecific antibodies, checkpoint inhibitors), stem cell transplantation, how doctors combine and sequence these treatments, a five-step decision framework, supportive care in China, and caregiver guidance.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Targeted therapy classes for blood cancer: TKIs, BTK inhibitors, BCL-2 inhibitors, proteasome inhibitors — and the molecular testing that guides selection
  • Immunotherapy beyond CAR T: monoclonal antibodies, bispecific antibodies, and checkpoint inhibitors — how they work and when they are used
  • Stem cell transplantation: autologous vs allogeneic, when it is appropriate, and what international patients need to plan
  • How doctors combine and sequence blood cancer treatments across induction, consolidation, relapse, and bridge-to-transplant phases
  • Five-step decision framework: confirm subtype, understand treatment phase, review categories, evaluate goals, consider MDT review
  • Supportive Care in China: TCM and integrative approaches to support treatment tolerance — with important safety note for immunotherapy patients

Important Facts

  • Blood cancer treatment is a dynamic sequence — not a single choice — requiring molecular subtype confirmation and staged evaluation
  • Bispecific antibodies are an increasingly important alternative to CAR T in relapsed or refractory settings — without requiring cell manufacturing
  • Stem cell transplant requires extensive pre-evaluation and cross-country coordination for international patients
  • MDT review provides a structured framework for evaluating all available treatment options at each stage of the blood cancer journey
April 29, 2026
Cell Therapy Guide

CAR T-Cell Therapy for Solid Tumours: CT041 and the Claudin18.2 Breakthrough

A calm, structured guide for international patients and caregivers on why CAR T has historically struggled in solid tumours, what the CT041 / Claudin18.2 breakthrough means for advanced gastric cancer, why long-term outcomes remain uncertain, how to evaluate eligibility through MDT review, a six-step decision framework, caregiver guidance, and how supportive care in China can complement CAR T treatment.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Why CAR T historically struggled in solid tumours: target variability, immunosuppressive microenvironment, physical barriers, and T-cell exhaustion
  • The CT041 (satri-cel) breakthrough: first randomised controlled CAR T trial in solid tumours, improved survival in CLDN18.2-positive gastric cancer
  • Why outcomes remain uncertain: limited follow-up, selected patient populations, durability variation, on-target off-tumour effects
  • How to assess eligibility: CLDN18.2 biomarker testing, prior treatment history, overall fitness, programme access, and timing
  • Six-step decision framework: confirm eligibility, understand treatment sequence, compare options, evaluate benefit vs uncertainty, assess access, use MDT review
  • Supportive Care in China: carefully coordinated TCM and integrative approaches to support patients during CAR T recovery

Important Facts

  • CAR T for solid tumours has moved from "not working" to "beginning to show results in specific cases" — but not yet to "reliably effective across patients"
  • CT041 targets CLDN18.2, which is overexpressed in gastric and GEJ cancers — eligibility depends on confirmed biomarker testing
  • Long-term outcomes remain uncertain: follow-up is limited, patient populations are highly selected, and durability varies
  • For international patients in China, structured MDT review confirms eligibility, sequences treatment, and sets realistic expectations before any commitment
April 28, 2026
Treatment Guide

How Do Targeted Cancer Drugs Find Cancer Cells?

A calm, structured guide for international patients and caregivers on how targeted cancer therapies work — covering molecular targeting mechanisms, why side effects still occur, how doctors use NGS and MDT review to select the right drug, a five-step decision framework for evaluating targeted therapy, and how supportive care in China can complement the treatment experience.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • How targeted drugs identify cancer cells: molecular markers such as HER2, EGFR, ALK, and BRAF — and why selectivity is not absolute
  • Four mechanisms of action: blocking growth signals, triggering apoptosis, anti-angiogenesis, and antibody-drug conjugates
  • Why side effects still occur — shared pathways between cancer and normal cells, and common drug-class-specific effects
  • How MDT review and molecular profiling determine whether targeted therapy is appropriate for a specific patient
  • Five-step decision framework: confirm molecular profile, understand treatment intent, evaluate drug access, plan for resistance, consider second opinion
  • Supportive Care in China: TCM and acupuncture to help manage fatigue, skin reactions, and digestive side effects alongside targeted therapy

Important Facts

  • Targeted therapy works only when specific molecular markers are confirmed — testing is not optional, it is the essential first step
  • Different mechanisms suit different cancers: blocking signals, triggering cell death, cutting blood supply, or delivering toxic payloads directly
  • Side effects can still occur because some molecular pathways are shared between cancer and normal cells
  • For international patients in China, MDT review confirms whether the recommended targeted drug is matched to the specific molecular profile
April 27, 2026
Treatment Guide

Are There Cases of Cancer Patients Cured Without Chemotherapy?

A calm, structured guide for international patients and caregivers on when cancer can be successfully treated without chemotherapy — covering early-stage disease managed with surgery or radiation alone, the real decision logic around chemo necessity, how to evaluate alternatives such as targeted or hormonal therapy, caregiver guidance, and how MDT review supports correct treatment planning in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Four direct answers: real cases without chemo, why some need it while others don't, whether avoiding it is a good strategy, and when to get a second opinion
  • What patients misunderstand: comparing outcomes without accounting for stage, tumour biology, and individual risk profile
  • Three-tier risk logic: low-risk localised disease vs intermediate-risk cases vs high-risk systemic disease — and when chemo is needed in each
  • Six-step decision framework: confirm stage, understand recurrence risk, weigh benefit vs burden, ask about alternatives, use MDT for complex cases
  • China context: how MDT-based evaluation helps determine whether chemotherapy is truly necessary
  • Caregiver guidance: balancing fear of chemo side effects with fear of under-treatment
  • Supportive Care in China: TCM and acupuncture to manage fatigue, nausea, and recovery alongside chemotherapy

Important Facts

  • Chemotherapy is not always necessary — early-stage, localised disease may be fully managed with surgery or radiation alone
  • The right question is not "Can cancer be cured without chemo?" but "Does this specific cancer at this stage require it?"
  • Alternatives such as targeted or hormonal therapy may replace chemotherapy for some cancers — but only if molecular testing confirms suitability
  • For international patients, MDT review helps clarify whether chemotherapy is essential, optional, or replaceable with another approach
April 26, 2026
Treatment Guide

How Does Prostate Cancer Stage Affect Treatment Decisions?

A calm, structured guide for international patients and caregivers on how prostate cancer stage determines whether surgery, radiation, hormone therapy, or chemotherapy is appropriate — covering the local-vs-systemic treatment concept, a six-step decision framework, risk classification, caregiver guidance, and how MDT review supports correct treatment sequencing in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Four direct answers: how stage influences treatment, why surgery isn't always best, when radiation is preferred, and when systemic therapy becomes necessary
  • The core concept: local disease requires local treatment; systemic disease requires systemic treatment
  • A six-step decision framework: confirm staging → understand risk → clarify goal → compare options correctly → MDT review → coordinated execution
  • Risk classification explained: low, intermediate, and high risk — and what each means for urgency and treatment intensity
  • Caregiver role: asking stage-first questions, preventing rushed decisions, and supporting long-term management

Important Facts

  • Stage determines which treatments are appropriate — choosing treatment before confirming stage often leads to suboptimal decisions
  • The right question is not "Which treatment is best?" but "Which treatment fits this stage and goal?"
  • For international patients, structured MDT review ensures staging and treatment logic are aligned before execution begins
  • Supportive care including TCM may help manage side effects during treatment but does not replace standard oncology care
April 24, 2026
Treatment Guide

Should You Have Surgery Immediately After Stomach Cancer Diagnosis?

A calm, structured guide for international patients and caregivers on stomach cancer surgery timing — covering when surgery is the first step, when neoadjuvant chemotherapy should come first, a six-step decision framework, caregiver guidance on avoiding panic-driven decisions, and how MDT review supports correct treatment sequencing in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Four direct answers: should surgery be immediate, what happens if surgery is too early, when is surgery the first step, and when to pause for a second opinion
  • Why stomach cancer often follows a sequence-based strategy — not a single immediate action
  • A six-step decision framework: confirm staging → ask about neoadjuvant therapy → clarify goal → understand full sequence → MDT review → coordinated execution
  • Caregiver guidance: how to channel urgency into structured action without driving harmful decisions
  • Supportive care in China: TCM and integrative approaches alongside standard treatment — not instead of it

Important Facts

  • Surgery timing in stomach cancer depends on stage and tumour characteristics — not simply how much time has passed since diagnosis
  • In locally advanced cases, neoadjuvant chemotherapy before surgery may lead to better outcomes than immediate surgery
  • The most useful question is not "Are we too late?" but "Do we have a clear treatment plan?"
  • A structured MDT consultation can clarify treatment sequencing before any travel or irreversible commitment is made
April 23, 2026
Breast Cancer Guide

Can Breast Cancer Be Fully Cured After Diagnosis?

A calm, structured guide for international patients and caregivers on what "cure" means in breast cancer — what stage and subtype determine about outcomes, why doctors use remission and disease-free survival instead of "cure", a six-step decision framework, caregiver roles in long-term follow-up, and how MDT review and supportive care in China fit into a complete treatment plan.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Four direct answers to common questions: can breast cancer be cured, what factors determine outcomes, why doctors avoid the word "cure", and when to seek a second opinion
  • Why "tumour removed" does not mean "all cancer risk is gone" — and what adjuvant therapy is actually for
  • A stage-by-stage overview: Stage 0–II (often curative intent), Stage III (higher risk), Stage IV (long-term control)
  • A six-step decision framework: stage, subtype, treatment goal, full sequence, MDT review, and coordinated execution
  • Caregiver roles across the full treatment timeline and how supportive care in China fits alongside standard treatment

Important Facts

  • Many early-stage breast cancers can be treated with curative intent — but ongoing monitoring remains important
  • The treatment goal (curative, adjuvant, or disease control) should be defined and understood before treatment begins
  • Tumour subtype — HR+, HER2+, or triple-negative — significantly affects treatment approach and recurrence patterns
  • For international patients, a structured MDT review can unify staging, treatment sequencing, and risk assessment
April 23, 2026
Treatment Guide

Can Cancer Come Back After It Is Removed?

A calm, structured guide for international patients and caregivers on cancer recurrence after surgery — what local, regional, and distant recurrence mean, why it can happen even after successful treatment, a four-step post-surgery action plan, a five-step decision framework for when recurrence is a concern, and how MDT-based review in China supports recurrence evaluation.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Four direct answers to common patient questions: can cancer return, why it can happen, does it mean surgery failed, and when to get a second opinion
  • The three types of recurrence (local, regional, distant) and why the distinction matters for treatment planning
  • A four-step post-surgery framework: pathology review, additional treatment discussion, follow-up planning, and second opinion
  • A five-step decision framework for responding when recurrence is suspected or confirmed
  • Caregiver roles and how supportive care in China fits alongside standard oncology treatment

Important Facts

  • Recurrence is not the end of decision-making — it is the start of a new treatment-planning stage
  • "The tumour was removed" is not the same as "all cancer risk is gone" — pathology, stage, and margins all matter
  • A second opinion is especially valuable when recurrence findings are unclear or treatment choices are complex
  • For international patients, recurrence care is not only a medical issue — it is also a coordination issue
April 22, 2026
Treatment Guide

What Happens If You Delay Cancer Treatment After Diagnosis?

A calm, structured guide for international patients and caregivers on what can happen if cancer treatment is delayed — covering when delay is medically appropriate, when it carries real risk, a seven-step decision framework, caregiver guidance, and how to distinguish a purposeful pause from an avoidable delay.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Four direct answers to the most common patient questions on treatment timing and delay
  • Why not all delays are equally dangerous — and what "medically purposeful waiting" actually means
  • A seven-step decision framework: how to tell a reasonable pause from a harmful delay
  • What patients should do if fear or confusion is preventing action after diagnosis
  • How caregivers can reduce avoidable delay — before and after treatment begins

Important Facts

  • The key question is not "Are we delayed?" but "Are we using this time to improve treatment planning?"
  • A second opinion is not necessarily delay — in many cases it is part of better treatment planning
  • For international patients, coordination delay and medical delay are different problems requiring different solutions
  • Supportive care in China may help with treatment burden, but should never replace standard cancer-directed care
April 7, 2026
Blood Cancer Treatment

Beijing Protocol: Haploidentical Stem Cell Transplant — Evidence for International Patients

A plain-language guide to the clinical evidence behind China's most widely used approach to half-matched donor transplantation — covering published outcomes data, patient eligibility, disease indications including leukaemia and aplastic anaemia, caregiver considerations, and post-transplant follow-up for international patients.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • What the Beijing Protocol is and how it differs from traditional matched-donor transplantation
  • Clinical evidence from peer-reviewed journals including Haematologica, Blood, and Journal of Clinical Oncology
  • Key outcomes data: survival rates comparable to fully matched sibling transplants
  • Modified protocols for older patients (aged 55–65) — Phase II trial evidence
  • Integration of CAR-T therapy with haploidentical HSCT for relapsed or refractory B-cell ALL

Important Facts

  • The Beijing Protocol is documented in international peer-reviewed journals — not centre-specific claims
  • Nearly every patient has a haploidentical family donor available — half-matched is sufficient
  • Eligibility for older patients has expanded significantly through modified conditioning regimens
  • A structured MDT review of existing records is the recommended first step for international patients
April 7, 2026
Lymphoma Guide

Follicular Lymphoma Treatment Options: What Should You Do Next?

A clear guide for international patients and caregivers on follicular lymphoma treatment — covering watchful waiting, immunotherapy, targeted therapy, chemotherapy, and CAR-T therapy for relapsed disease, with guidance on when to treat and how MDT evaluation supports timing decisions.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Why watchful waiting is a legitimate first approach for some follicular lymphoma patients
  • Immunotherapy: when it is used alone and when combined with chemotherapy
  • Targeted therapy options for progression or relapse
  • CAR-T therapy for relapsed or refractory follicular lymphoma — eligibility and process
  • How to think about treatment timing — the most important and often hardest question

Important Facts

  • The key question for follicular lymphoma is often "when to treat" — not just "what to treat with"
  • Watchful waiting is an active, monitored strategy — not inaction
  • A second opinion can help confirm that monitoring or treatment timing is appropriate
  • A structured MDT review is the most effective starting point for international patients
April 7, 2026
Lymphoma Guide

Diffuse Large B-Cell Lymphoma Treatment Options: What Should You Do Next?

A clear guide for international patients and caregivers on DLBCL treatment approaches — covering first-line chemoimmunotherapy, radiation, targeted therapy, stem cell transplant, and CAR-T therapy for relapsed or refractory disease, with guidance on second opinion and MDT evaluation.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Standard first-line treatment: chemotherapy combined with immunotherapy
  • When radiation therapy is used in DLBCL — and when it is not
  • Targeted therapy options for specific molecular subtypes
  • Stem cell transplant: when it is considered and what eligibility involves
  • CAR-T therapy for relapsed or refractory DLBCL — eligibility and process

Important Facts

  • Not all DLBCL cases are the same — molecular subtype and stage drive treatment decisions
  • A second opinion can help confirm diagnosis and evaluate whether the proposed treatment is optimal
  • CAR-T therapy is typically used after prior treatment lines — not as first-line therapy
  • A structured MDT review is the most effective starting point for international patients
April 6, 2026
CAR-T Guide

Side Effects of CAR-T Therapy: What Patients Should Know

A calm, clear guide for international patients and caregivers on what CAR-T therapy side effects to expect — covering cytokine release syndrome (CRS), neurological symptoms (ICANS), blood count changes, infection risk, fatigue, and what hospital monitoring looks like in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Cytokine release syndrome (CRS): what it is, when it happens, and how it is managed
  • Neurological symptoms (ICANS): what patients may experience and why
  • Blood count changes, infection risk, and fatigue during recovery
  • Why understanding side effects helps — not hinders — treatment decisions
  • What hospital monitoring looks like for international patients in China

Important Facts

  • CAR-T side effects are immune-related, not drug toxicity — they work differently from chemo
  • Most side effects occur in the first days to weeks after infusion under hospital monitoring
  • Side effects should be understood alongside disease stage and treatment goals — not in isolation
  • A structured MDT review is the right first step before making CAR-T decisions
April 6, 2026
Treatment Guide

CAR-T vs Targeted Therapy: What's the Difference and How Do You Decide?

A clear guide for international patients comparing CAR-T therapy and targeted therapy — covering how each works, the key difference between molecular precision and immune cell engineering, when each is typically used, and how a multidisciplinary review helps determine the most appropriate treatment sequence.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • How targeted therapy and CAR-T therapy differ — molecular blocking vs immune cell reprogramming
  • Why targeted therapy is often used earlier and CAR-T typically comes after prior treatment lines
  • What makes the comparison complex and how an MDT review brings clinical clarity
  • Step-by-step preparation guide for international patients evaluating advanced treatment options
  • What to expect from structured evaluation and multidisciplinary decision support in China

Important Facts

  • Targeted therapy blocks cancer pathways; CAR-T engineers immune cells — they are fundamentally different strategies
  • The question is not which is "better" but which is appropriate at this stage of the disease
  • Molecular profile and treatment history determine which option is even available
  • A structured MDT review is the appropriate starting point before any advanced treatment decision
April 6, 2026
Treatment Guide

CAR-T vs Chemotherapy: What's the Difference and How Do You Decide?

A clear guide for international patients comparing CAR-T therapy and chemotherapy — covering how each works, when each is typically used, side effect profiles, and how a multidisciplinary review helps determine the most appropriate treatment at each stage of the cancer journey.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • How CAR-T therapy and chemotherapy differ — mechanism, timing, and side effect profiles
  • Why CAR-T is typically used after relapse, not as first-line treatment
  • What factors make treatment decisions complex and how an MDT review brings clarity
  • Step-by-step preparation guide for international patients comparing treatment options
  • What to expect from structured evaluation and MDT-based decision support in China

Important Facts

  • CAR-T and chemotherapy are not interchangeable — they serve different roles at different stages
  • The question is not which is "better" but which is appropriate for this patient at this stage
  • Treatment decisions are clinical determinations, not patient choices made in isolation
  • A structured MDT review is the appropriate first step before any major treatment decision
April 5, 2026
Treatment Guide

Lymphoma Treatment After Relapse: What Options Exist and How to Decide

A clear guide for international patients and caregivers facing lymphoma relapse — covering the main treatment options (salvage chemotherapy, targeted therapy, stem cell transplant, CAR-T), why a second opinion is especially valuable at this stage, and how to access structured evaluation and MDT review in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Five treatment approaches at relapse: salvage chemotherapy, targeted therapy, immunotherapy, stem cell transplant, and CAR-T
  • Why relapse is one of the most important moments to seek a structured second opinion or MDT review
  • What factors doctors reassess at relapse and why treatment becomes highly personalized
  • How international patients prepare medically and logistically for relapse evaluation in China
  • What to expect in terms of monitoring, strategy adjustment, and advanced therapy timing after relapse

Important Facts

  • Lymphoma relapse does not mean treatment options have run out — it is a recognized stage requiring strategy reassessment
  • Treatment at relapse is highly individualized: what was used before, how long it worked, and current disease status all matter
  • A second opinion or MDT review at relapse often provides the clearest picture of available options and sequencing
  • You are not starting over — you are continuing a treatment journey, with new decisions ahead
April 5, 2026
Treatment Guide

Lymphoma Treatment Options Explained: A Clear Guide for Patients and Families

A clear guide to the main treatment approaches for lymphoma — covering chemotherapy, immunotherapy, targeted therapy, radiation, stem cell transplant, and CAR-T therapy — and how international patients can access structured evaluation and treatment coordination in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Six main treatment approaches: chemotherapy, immunotherapy, targeted therapy, radiation, stem cell transplant, and CAR-T
  • Why lymphoma subtype — DLBCL, Hodgkin, follicular, mantle cell — determines the treatment approach
  • When CAR-T therapy is typically considered and what eligibility involves for international patients
  • How international patients prepare medically and logistically for lymphoma evaluation in China
  • The role of caregivers and why shared decision-making matters in lymphoma care

Important Facts

  • Lymphoma is not a single disease — subtype confirms the treatment direction before any plan is formed
  • Treatment decisions are often complex and personalized: a structured second opinion or MDT review can provide important clarity
  • CAR-T therapy is typically considered after relapse, and eligibility requires thorough multidisciplinary evaluation
  • Understanding your options does not remove uncertainty — but it helps you move forward with greater confidence
April 5, 2026
Treatment Guide

Multiple Myeloma Treatment After Relapse: What Options Exist and How to Decide

A clear guide for international patients and caregivers facing myeloma relapse — covering the main treatment options (new drug combinations, targeted therapies, CAR-T), why a second opinion matters most at this stage, and how to access structured evaluation and MDT review in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Four treatment approaches at relapse: changing drug combinations, novel therapies, CAR-T therapy, and clinical strategy adjustments
  • Why relapse is one of the most important moments to seek a structured second opinion or MDT review
  • What factors doctors assess at relapse and why treatment becomes highly personalized
  • How international patients prepare medically and logistically for relapse evaluation in China
  • What to expect in terms of monitoring, strategy adjustment, and advanced therapy timing after relapse treatment

Important Facts

  • Myeloma relapse does not mean treatment options have run out — it is a recognized part of long-term disease management
  • Treatment at relapse is highly personalized: what was used before, how long it worked, and current disease status all matter
  • A second opinion or MDT review at relapse often provides the clearest picture of available options and timing
  • You are not starting from zero — you are continuing a treatment journey, with new decisions ahead
April 5, 2026
Treatment Guide

Multiple Myeloma Treatment Options Explained: A Clear Guide for Patients and Families

A clear guide to the main treatment pathways for multiple myeloma — covering targeted therapy combinations, stem cell transplant, maintenance, relapsed disease, and CAR-T therapy — and how international patients can access structured evaluation and treatment coordination in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Five main treatment approaches: targeted therapy combinations, stem cell transplant, maintenance therapy, relapsed disease options, and CAR-T
  • What determines treatment selection — stage, risk classification, prior treatments, and patient health
  • When CAR-T therapy is typically considered and what eligibility involves
  • How international patients prepare medically and logistically for myeloma evaluation in China
  • The role of caregivers in long-term myeloma care and decision-making

Important Facts

  • Multiple myeloma is often managed as a long-term condition — treatment evolves across phases rather than following a single fixed path
  • Treatment selection depends on disease stage, risk classification, transplant eligibility, and prior treatment history
  • CAR-T therapy is typically considered after relapse, and eligibility requires thorough MDT-based evaluation
  • Understanding your options does not make the journey simple — but it makes it more navigable
April 4, 2026
Decision Guide

CAR-T Therapy for Multiple Myeloma: Who Is Eligible and What to Expect

A guide for international patients on CAR-T therapy eligibility for multiple myeloma — covering disease status, prior treatment requirements, the step-by-step process, preparation, and what to expect when coordinating care in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Five eligibility factors: disease status, prior therapies, overall health, disease burden, and MDT-based review
  • Six-step treatment process from evaluation through leukapheresis, cell engineering, conditioning, infusion, and monitoring
  • Why eligibility assessment for myeloma CAR-T requires pathology, imaging, and multidisciplinary discussion
  • What international patients should prepare medically and logistically before and during treatment
  • The role of caregivers and why their own wellbeing also needs planning

Important Facts

  • CAR-T for myeloma is typically considered after relapse or when prior therapies are no longer working
  • Eligibility requires a thorough clinical evaluation — not a simple checklist
  • International patients often begin with a remote MDT consultation before traveling to confirm appropriateness
  • Clarity before commitment: understanding the process reduces both uncertainty and avoidable urgency
April 4, 2026
Decision Guide

CAR-T Therapy for Lymphoma: Who Is Eligible and What to Expect

A detailed guide for international patients on CAR-T therapy eligibility for lymphoma — covering eligibility criteria, the step-by-step treatment process, how to prepare medically and logistically, what to expect in China, and why starting with a structured MDT review matters.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Five eligibility factors doctors assess: lymphoma subtype, disease status, prior treatments, overall health, and disease burden
  • Six-step process from evaluation through leukapheresis, cell engineering, conditioning, infusion, and monitoring
  • Why eligibility for CAR-T requires pathology confirmation, PET-CT review, and multidisciplinary discussion
  • What international patients should prepare medically and logistically before and during treatment
  • The role of caregivers throughout CAR-T treatment — and why their wellbeing also needs planning

Important Facts

  • CAR-T is not a first-line treatment — it is typically considered after relapse or when prior therapies have been insufficient
  • Eligibility is not a simple checklist: it requires pathology, imaging, and MDT review before any treatment is confirmed
  • International patients often begin with a remote MDT consultation before traveling to confirm appropriateness
  • Clarity before commitment: taking time to understand the full process reduces both uncertainty and avoidable urgency
April 3, 2026
Decision Guide

Travel for Treatment: What Cancer Patients and Families Should Prepare

A step-by-step preparation guide for international cancer patients and caregivers planning treatment in China — covering medical records, MDT review, visa and accommodation logistics, financial planning, emotional readiness, caregiver preparation, and post-treatment continuity of care.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • What medical documents to gather before traveling and why completeness matters
  • Why starting with a remote MDT review often reduces the need for urgent travel
  • Visa, accommodation, and transport considerations specific to cancer patients
  • Emotional and caregiver preparation — the often-overlooked dimension of treatment travel
  • What to expect in the first days after arrival and how post-treatment transition is planned

Important Facts

  • A well-prepared medical file is the most important single step before travel — incomplete records delay evaluation
  • Many international patients clarify treatment options through a remote MDT consultation before booking flights
  • Caregiver preparation is as important as patient preparation — fatigue and shared responsibility need planning
  • Treatment abroad involves coordinating two healthcare systems: a clear post-treatment plan before discharge is essential
April 2, 2026
Treatment Guide

CAR-T Therapy in China: What Foreign Patients Should Know

A guide to CAR-T cell therapy for lymphoma in China — how it works, who may be eligible, what the treatment process involves for international patients, and why a structured second opinion matters before deciding.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Step-by-step explanation of the CAR-T therapy process from cell collection to monitoring
  • Which types of lymphoma are most commonly considered for CAR-T
  • Why eligibility is strict and CAR-T is not a first-line treatment
  • Key risks including cytokine release syndrome (CRS) and how hospitals manage them
  • How to prepare medically and logistically for a CAR-T treatment visit to China

Important Facts

  • CAR-T therapy in China is available to eligible foreign patients, but requires thorough clinical evaluation before any treatment is arranged
  • Most patients begin with a remote second opinion or MDT review before traveling to determine suitability
  • Post-infusion monitoring requires staying near the treating hospital — travel planning must account for this
  • A well-informed, unhurried approach to decision-making is more important than speed

Need Personalised Cancer Care Guidance?

Our medical coordinators can help you understand your options, connect with oncology specialists, and navigate cancer care in China.

Get ConsultationAll Resources